Article preparation
edit| Headquarters | , United States |
|---|---|
Key people |
|
Number of employees | <500 (2013) |
| Parent | Agilent Technologies |
| Website | Official website |
ACEA Biosciences is a small (<500 employees) American biological assay development company based in San Diego, California.[1] The company marketed the first high throughput instrument for label-free, electrical impedance based cellular assays under the brand "Cellkey".[2]
ACEA exploits a technology called "label-free electrical impedance detection",[3] which was initially described in 1984.[2]
One source of revenue for ACEA has been government grants. In 2013, the company received a small, short term grant (US$80,000 over 6 months) from the USEPA to "develop cell lines, protocols and data analysis methods to assess the toxic effects of environmental pollutants."[1]
As of December 2009[update], the company's chief executive officer was James O'Connell.[4] As of March 2011[update], the company's chief technology officer was Xiaobo Wang.[5] For at least the period between March 2011 and November 2014, the Vice President and Senior Director for Research and Development was Yama Abassi.[6][5][7]
Agilent acquired ACEA Biosciences in November 2018 for US$250 million.[8]
Products
editOne of company's products is the "xCELLigence plate reader", a device which can be used to monitor the movement patterns of small organisms (such as hookworms) and coverage or movement properties of adherent cultured cells in response to administered drugs or other chemicals, such as toxins.[6] A version of the reader has been specialized to assess the beating pattern of cardiac muscle cells in culture, the "RTCA cardio" device.[6] A related product, "RT-CES", has been used to "monitor cell growth in real time", the associated growth substrate referred to as an "E-plate".[9]
The company's xCELLigence product was co-developed with and marketed globally through a partnership with Roche Applied Science.[5] ACEA also engaged Vivo Biosciences to develop assays for the xCELLigence system incorporating Vivo's proprietary HuBiogel technology.[10] Roche Applied Science owns the trademark on the product's name,[5] though the underlying intellectual property is owned by ACEA.[11]
Competitors
editAs of 2010, and restricting to just those companies which develop assay devices measuring electrical impedance as a function of cell-surface contact, ACEA has two competitors: Applied BioPhysics and MDS Analytical Technologies.[2] By 2011 the competitor number had increased to include Corning Biosciences, Bionas and ibidi GmbH.[12]
References
edit- ^ a b "San Diego Companies Awarded EPA Grants To Study Health, Environment". KPBS. Television license held by California State University Board of Trustees. City News Service. 13 June 2013. Retrieved 14 Feb 2020.
{{cite news}}: CS1 maint: url-status (link) - ^ a b c Wu, Ge (2010). "Chapter 11. Assays Based on Integrated Cell System Properties". Assay Development: Fundamentals and Practices. Hoboken, New Jersey: Wiley. pp. 298–301. ISBN 9780470583111 – via Google Books (Preview).
- ^ Dunbar SA, Zhang H, Tang YW (September 2013). "Advanced Techniques for Detection and Identification of Microbial Agents of Gastroenteritis". In Burnham, Carey-Ann D. (ed.). Automation and Emerging Technology in Clinical Microbiology. Clinics in Laboratory Medicine Vol 33 Num 3. Elsevier. p. 545. ISBN 0323188605 – via Google Books (Preview).
- ^ Staff (14 Dec 2009). "International Report: Concord Medical Reports IPO Pricing on NYST of 12M Shares". Medical Device Daily. Thomson Reuters – via HighBeam Research.[permanent dead link]
- ^ a b c d Staff (2 Mar 2011). "ACEA Biosciences, Inc. Announces New Patent; Broad Claims Granted for Cytotoxicity Profiling and Chemical Compound Testing on the xCELLigence System". Biotech Week – via HighBeam Research.[permanent dead link]
- ^ a b c Dance, Amber (30 November 2012). "Hit Parade". The Scientist. Midland, Ontario: LabX Media Group. Retrieved 14 Feb 2020.
{{cite news}}: CS1 maint: url-status (link) - ^ Labant, MaryAnn (15 November 2014). "Weaving a Stronger Drug Safety Net". Genetic Engineering & Biotechnology News (paper). Vol. 34, no. 20. Mary Ann Liebert. p. 1. Retrieved 14 Feb 2020.
{{cite news}}: CS1 maint: url-status (link) - ^ Phillippidis, Alex (12 July 2019). "Agilent Expands Cell Analysis Business with Planned $1.2B BioTek Acquisition". Genetic Engineering & Biotechnology News. Retrieved 9 July 2020.
Staff (26 September 2018). "Agilent Acquires Cell Analysis Tools Developer ACEA Biosciences". Genetic Engineering & Biotechnology News. Retrieved 9 July 2020. - ^ Liu X, Zhang H, Lai L, Wang X, Loera S, Xue L, He H, Zhang K, Hu S, Huang Y, Nelson RA, Zhou B, Zhou L, Chu P, Zhang S, Zheng S, Yen Y (1 May 2013). "Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers". Clinical Science. 124 (9). London: Portland Press: 571. PMC 3562074 – via Pubmed Central.
- ^ Staff (22 Nov 2010). "Biotechnology Company Deals With Other Biotechnology Companies: Oct. 1 - Nov. 19, 2010". BioWorld Insight. Thomson Reuters. Archived from the original on 13 March 2016 – via HighBeam Research.
- ^ US patent 7876108, Abassi, Yama A.; Wang, Xiaobo & Xu, Xiao, "Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays", issued 25 Jan 2011, assigned to Acea Biosciences, Inc.
- ^ Eickhoff J, Choidas A (2011). "Chapter 2. Screening for Kinase Inhibitors: From Biochemical to Cellular Assays". In Klebl B, Müller G, Hamacher M (eds.). Protein Kinases as Drug Targets. Methods and Principles in Medicinal Chemistry Vol 49. Weinheim, Germany: Wiley-VCH. 2.3.5 Label-Free Technologies. ISBN 9783527633494 – via Google Books (Preview).